Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: November 30, 2005 (Second Quarter of Fiscal 2006)
Business Overview: Neogen operates two reportable segments: Food Safety (diagnostic test kits for toxins, bacteria, and allergens) and Animal Safety (veterinary instruments, consumables, and rodenticides). The company is incorporated in Michigan with principal executive offices in Lansing.
Key Financial Metrics
| Metric | Three Months Ended Nov 30, 2005 | Six Months Ended Nov 30, 2005 |
|---|---|---|
| Net Sales | $18,256,000 | $35,034,000 |
| Gross Margin | $9,490,000 (52%) | $18,331,000 (52%) |
| Operating Income | $3,347,000 | $6,452,000 |
| Net Income | $2,213,000 | $4,353,000 |
| Diluted EPS | $0.26 | $0.51 |
| Cash & Marketable Securities | $3,933,000 | N/A |
| Working Capital | $27,033,000 | N/A |
| Long-Term Debt | $0 (No amounts drawn on $17.5M line) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% in the quarter and 8% year-to-date compared to the prior year. Food Safety sales rose 5% (quarter) and 6% (YTD), while Animal Safety sales rose 8% (quarter) and 11% (YTD).
- Margin Expansion: Gross margin improved from 47% to 52% in the quarter and from 48% to 52% year-to-date, driven by manufacturing efficiencies and a favorable product mix.
- Profitability: Operating income increased 41% in the quarter ($3.35M vs $2.38M) and 34% year-to-date ($6.45M vs $4.81M). Net income rose 32% in the quarter and 34% year-to-date.
- Expense Trends: Sales and marketing expenses increased as a percentage of revenue (21% to 22% YTD), while General and Administrative expenses remained stable at 8% of revenue.
- Balance Sheet: Accounts receivable increased by $2.4M, extending days outstanding from 56 to 60 days. Inventories increased by $1.0M to support expected sales.
Outlook, Risks, and Unusual Items
- Guidance: Management explicitly states it does not provide forecasts of future performance. Historical results may not be indicative of future performance.
- Subsequent Event (Acquisition): On December 20, 2005, Neogen acquired the dairy antibiotic business of UCB (Belgium) for approximately $14.7 million in cash plus contingent payments up to $4.3 million. The acquired business had sales of approximately $8.5 million in the prior year.
- Liquidity: The company maintains a $17.5 million unsecured revolving line of credit with no amounts drawn as of November 30, 2005. Management believes existing cash and credit lines are sufficient for foreseeable needs, though future acquisitions or product commercialization may require additional financing.
- Risks: Key risks include competition, dependence on key employees, weather impacts on agriculture, integration of acquisitions, and foreign currency exposure (primarily British Pound), though the company does not currently hedge these exposures.
- Stock Repurchase: The Board has authorized the purchase of up to 1,250,000 shares; 893,000 shares had been purchased and retired as of November 30, 2005.
Investor Verification Checklist
- Acquisition Integration: Verify the financial impact and integration timeline of the December 2005 UCB dairy antibiotic business acquisition.
- Receivables Quality: Monitor the trend in days sales outstanding (increased to 60 days) and the adequacy of the allowance for doubtful accounts ($522,000).
- Inventory Levels: Assess whether the $1.0M increase in inventory aligns with sales velocity to avoid obsolescence risks.
- Segment Performance: Confirm continued growth in the Animal Safety segment (11% YTD growth) versus the more modest growth in Food Safety (6% YTD).
- Capital Needs: Evaluate if the $17.5M credit line and current cash balances are sufficient for planned R&D commercialization and future M&A activity.